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METHODS OF OBTAINING EVIDENCE FROM PUBLISHED SURVIVAL DATA FOR
USE IN DECISION ANALYTIC MODELS
Trueman D, Livings C, Mildred M
Abacus International, Bicester, Oxfordshire, UK
OBJECTIVES: Decision analytic models used in cost-effectiveness analysis often
rely upon long-term survival data from observational studies for which patient-
level data are not available. Analysts may therefore be required to digitally extract
survival data from published Kaplan-Meier plots and fit parametric survival curves,
in order to provide estimates of time until an event or a per-cycle probability of an
event occurring. Methods used in practice include minimising a sum of squared
residuals statistic (using Microsoft Excel Solver) in order to estimate desired pa-
rameters for a given distribution. A technique recently published by Guyot et al
provides a methodology for reconstructing a patient-level dataset from published
Kaplan-Meier plots, using the tabulated numbers at risk to incorporate censoring.
An alternative reconstructing methodology which does not account for censoring
is also explored. We sought to establish the accuracy of these methods.METHODS:
The techniques described were tested on a published dataset (Gehan). Patient-level
datasets were reconstructed based on the digitised curves. Results of survival mod-
els fitted using these techniques are presented for comparison against models
fitted using the original data. RESULTS: Median survival times using a Weibull
regression on the original dataset was 7.2 and 25.7 months for the placebo and
treatment arms, respectively. Using the minimisation of squared residuals ap-
proach resulted in median times of 6.1 and 25.0 months. The reconstructed patient-
level approach incorporating censoring yielded median times of 7.1 and 28.9
months, whilst the alternative technique (without censoring) resulted in median
times of 7.1 and 27.6 months. CONCLUSIONS: The reconstructed patient-level da-
tasets can be interrogated as per patient-level survival data, allowing diagnostic
statistics such as the Akaike Information Criterion to be estimated and plots of
log-cumulative hazard to be generated, which aid the analyst in selecting appro-
priate distributions and assumptions. It is therefore suggested that these tech-
niques become the preferred methods.
PRM82
VERIFICATION OF PROPORTIONAL HAZARDS ASSUMPTION IN COST-
EFFECTIVENESS ANALYSIS (CEA)
Zerda I, Gwiosda B, Plisko R
HTA Consulting, Krakow, Poland
OBJECTIVES: The Cox proportional hazards (PH) model is commonly used to de-
scribe time-to-event data in CEAs. Although this methodology has many advan-
tages, it requires proportional hazards, a strong assumption that is rarely checked
and hardly verifiable in case of lack of individual patient data (IPD). Time-to-event
outcomes are usually reported in clinical studies by Kaplan-Meier plots with me-
dian time-to-events or hazard ratios. In CEAs, the common practice is to digitalize
the published Kaplan-Maier graphs and fit parametric model to predict the treat-
ment effects. However all these data are insufficient to get unambiguous and ob-
jective results of conventional PH assumption tests. Our aim was to present two
alternative algorithms of how PH assumption may be checked based on data re-
ported in clinical studies. METHODS: The first method applies the algorithm pro-
posed in Guyot 2012 (BMC Medical Research Methodology 2012, 12:9) which closely
approximates the original Kaplan-Meier curves from published graphs. Advanced,
analytical techniques were adopted to estimated IPD to check PH assumption. The
second algorithm utilizes the Weibull model fitted to digitalized Kaplan-Maier
data. Statistical tests for comparison of the fitted shape coefficients were applied to
verify PH assumption (in Weibull model if difference between shape coefficients is
statistically insignificant PH assumption is accepted). The accuracy of both algo-
rithms was assessed in theoretical computer simulations and by comparing results
of published IPD analysis and discussed algorithms on empirical data from trials
systematically identified in Medline. RESULTS: The validation exercise established
there was agreement in results of PH testing by IPD analysis and proposed algo-
rithms. The inconsistence areas were specified. CONCLUSIONS: The algorithms
are a reliable tools for testing PH assumption of time-to-event data in case of lack of
IPD. It is recommended that all CEAs where survival analysis was included should
test PH assumption using at least one of proposed methods.
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COMPARING METHODS OF MIXED TREATMENT COMPARISONS IN HEALTH
ECONOMIC MODELS
Vemer P1, Al MJ2, Oppe M1, Rutten-van Mölken MP2
1iMTA, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands
OBJECTIVES: Decision-analytic cost-effectiveness (CE) models combine many dif-
ferent parameters, which are often obtained after indirect meta-analysis. The
choice of method may affect CE estimates. We aimed to compare different methods
of indirect meta-analysis, especially with respect to health economic (HE) out-
comes as the costs per QALY. METHODS: A reference patient population
(N50,000) was simulated, from which sets of trials were drawn, comparing two of
four fictitious interventions. Heterogeneity was added in pre-specidifed scenarios
by drawing from subpopulations. Trial-specific parameter estimates were com-
bined using Bucher’s direct and indirect comparisons, and the mixed treatment
comparison (MTC) methods by Song, Puhan and Lu/Ades (fixed and random ef-
fects). Pooled parameters were entered into a HE Markov model. We studied
whether differences were systematic by repeating the sampling and indirect meta-
analysis 1,000 times. Estimated parameters and HE outcomes were compared using
coverage, bias, mean absolute deviation (MAD) and statistical power. RESULTS:
Bucher’s methods are outperformed by the MTC methods, generally overestimat-
ing uncertainty and having a relatively large MAD. HE outcomes for Song have low
MAD and bias, but uncertainty is overestimated. Puhan’s method does not overes-
timate uncertainty and generally is the closest to the true parameter value, regard-
less of heterogeneity. Both lead to the least amount of uncertainty reflected in the
CE acceptability curve (CEAC). Lu/Ades fixed effects performs slightly worse than
Puhan and Song in terms of bias and MAD. Uncertainty is generally overestimated,
regardless of heterogeneity. It is also slightly less certain in the CEAC. Only with
considerable heterogeneity does the Lu/Ades random effects model have the low-
est bias. It still shows large MAD and uncertainty is almost always overestimated.
CONCLUSIONS: Regardless of heterogeneity, combining direct and indirect evi-
dence improves results. HE outcomes produced with Puhan’s method have the best
statistical properties.
PRM84
USING PROPORTIONAL HAZARD MODELS TO PREDICT PRICE CHANGES OF
ONCOLOGY DRUGS IN THE UNITED STATES
Wang BCM1, Tsang KP2, Patel P3
1Adjility Health, New York, NY, USA, 2Virginia Tech, Blacksburg, VA, USA, 3Adjility Health,
London, UK
OBJECTIVES: Predicting the price change percentages and timings of drugs is im-
portant to policy makers, pharmaceutical companies, and even investment firms.
As a case study, we utilize a set of oncology drugs in the US and apply hazard
models to perform the predictions. METHODS: Using data from First DataBank
(2003-2012), we have a panel of ex-factory drug prices for drug packs for 18 brand
names. We convert the data into survival time data by calculating the time dura-
tion between each price change, which results in a total of 200 price increases and
38 censored outcomes. In our hazard models, we include the FDA approval date for
each drug as an exogenous variable to answer the following questions: 1) how is the
percentage change in price related to the time since the last price change and the
time since FDA approval, and 2) does the probability of a price change depend on
the time since FDA approval? We use Cox Proportional Hazard models for
prediction. RESULTS: The average “event” is a price increase of 5%. For percentage
changes in price, we find that for each additional month of constant price, the
subsequent price increase drops by 0.08%. For a second order effect, we find that
the negative effect of time since last price change is decreasing. Also, time since
FDA approval has a large and significant effect: for each additional month since
FDA approval, the subsequent price increase drops by 0.03%. The average duration
between events is 8.8 months. The Cox model shows that for each additional
month since FDA approval, the “risk” of a price increase increases by 0.7%. Simi-
larly, there is a second order effect showing this risk diminishing over time.
CONCLUSIONS: Hazard models can predict the timing and percentage of price
changes in oncology drugs in the United States.
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INTERNAL VALIDATION OF THE SYREON DIABETES MODEL
Merész G1, Nagyjanosi L1, Nagy B2, Dessewffy Z3, Vokó Z4, Kalo Z5
1Syreon Research Institute, Budapest, Hungary, 2ELTE, Budapest, Hungary, 3Novartis Hungary,
Budapest, Hungary, 4Eötvös Loránd University, Budapest, Hungary, 5Eötvös Loránd University,
Budapest, Hungary
OBJECTIVES: The Syreon type 2 diabetes model projects outcomes for populations
over time with taking into account baseline patient characteristics, history of com-
plications, changes in physiological parameters, diabetes treatment and manage-
ment strategies, and screening programs. The objective of this study was to eval-
uate the internal validity of the health economic model and confirm the predictive
accuracy of the model variables. METHODS: The internal validation was designed
according to published methodological standards. A total of 71 second- (internal)
order validation analyses were performed across a range of complications and
model outcomes for each submodel (ischemic heart disease, retinopathy, hypogly-
caemia, nephropathy, neuropathy, foot ulcer, peripherial vascular disease, stroke
and ketoacidosis). Published studies were reproduced by recreating cohorts ac-
cording to important patient characteristics, treatment patterns and management
strategies. The model simulated the progress of the cohorts until the published
studies’ time horizon. The published and simulated incidence rates were then
compared and the validation analysis was considered successful, if the published
incidence rates fell within the confidence interval of the simulated incidence rates.
RESULTS: First results show that the model simulations were generally close to
published outcomes. No significant differences between the simulated and the
published incidence rates and life expectancy were observed. The average absolute
difference in the case of transition probability parameters was 0,056%. The model
predicted an average absolute difference of 0.025% in life expectancy between the
published data simulated data. A correlation plot of published versus simulated
results showed a trend line with a gradient of close to 1. CONCLUSIONS: Based on
the first results the Syreon health economic model correctly replicates the devel-
opment and progression of diabetes and can be used to evaluate the cost-effective-
ness of potential diabetes prevention and treatment programs. External validation
is needed to further confirm the predictive accuracy and reliability of the model.
PRM86
UTILIZING INDIRECT TREATMENT COMPARISONS IN METASTATIC
CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Wasiak R1, Joulain F2, Lambrelli D1, Trask PC3, Sartor O4
1United BioSource Corporation, London, UK, 2Sanofi-Aventis, Massy, France, 3Sanofi, Cambridge,
MA, USA, 4Tulane University, New Orleans, LA, USA
OBJECTIVES: To compare the efficacy of two treatments in mCRPC using alterna-
tive approaches to indirect treatment comparisons (ITCs). METHODS: The TROPIC
and COU-AA-301 trials demonstrated that cabazitaxelprednisone (CbzP) and
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abirateroneprednisone (AbP) improve overall survival (OS) in patients with
mCRPC vs. mitoxantroneP (MP) or P alone, respectively. Examination of patient
and disease characteristics noted differences in the exposure to docetaxel and
discontinuation of docetaxel due to progressive disease. The current study: 1) con-
ducted systematic literature reviews of second-line treatment studies; 2) reviewed
NICE and IQWIG submissions; 3) reviewed the initial and updated OS data from the
TROPIC and COU-AA-301 studies; 4) interviewed clinical experts; and 5) performed
a meta-analysis of two first-line (1L) mCRPC studies to inform the ITC on the OS for
the two treatments and connect the network. Three comparisons were performed
using hazard ratios (HRs) for the MP vs. P: 1.0 (clinical expert opinion), 0.97 (1L
studies meta-analysis), and 0.90 (survival curve extraction). The Bucher ITC was
used with a HR (CbzP vs. AbP)1 favoring CbzP.RESULTS:Results based on updated
OS data were consistent across methodologies, with HR(OS, clinical)0.97 (95%CI:
0.78-1.21), HR(OS, meta-analysis)0.95 (95%CI: 0.69-1.30) and HR(OS, extrac-
tion)0.88 (95%CI: 0.63-1.21), but all HRs were not significantly different. This was
observed in the docetaxel-resistant subgroup as well; with HR(OS, clinical) 0.95
(95%CI: 0.70-1.28), HR(OS, meta-analysis) 0.92 (95%CI: 0.63-1.34) and HR(OS, ex-
traction)0.85 (95%CI: 0.59-1.24). These are different from the results presented in
the IQWIG submission assuming that MP has the same effect as P alone based on
initial OS data. CONCLUSIONS: Differences in results highlight the dependency of
ITCs on efficacy assumptions. Lack of equivalence in disease, comparators or pa-
tient characteristics contribute to uncertainty regarding conclusions, which fur-
ther emphasizes the fact that randomized prospective clinical trials are best suited
to fully evaluate the efficacy and safety of cancer treatments.
RESEARCH ON METHODS - Patient-Reported Outcomes Studies
PRM87
CROSS-CULTURAL VALIDATION OF THE HUNTINGTON QUALITY OF LIFE
INSTRUMENT IN SPAIN
Khemiri A1, Clay E2, Trigo P3, Yebenes J3, Toumi M4
1Creativ-Ceutical, Tunis, Tunisia, 2Creativ-Ceutical, Paris, France, 3Hospital Ramón y Cajal,
Madrid, Spain, 4University Claude Bernard Lyon 1, Lyon, France
OBJECTIVES: The Huntington Quality of Life Instrument (H-QoL-I) is the first self-
reported, disease-specific instrument developed to assess the health-related qual-
ity of life (HRQoL) of patients with Huntington’s disease (HD). It was originally
developed and validated for France and Italy, and later also validated for Germany,
Poland and the USA. This study aimed to validate the Spanish version of H-QoL-I
cross-culturally. METHODS: The original questionnaire included three subscales
assessing motor functioning, psychology and socializing (11 items). The instru-
ment was translated forwards and backwards by native speakers. A survey was
conducted with 59 patients. Face validity was tested through item completion and
overall understanding. Internal validity was tested, assessing internal consistency,
correlation matrix using item/dimension correlation and factorial structure. Exter-
nal validation was performed versus motor symptoms, behavioral symptoms, in-
dependence, and the EuroQoL 5D (EQ-5D). Differential item functioning (DIF) anal-
yses were performed versus data from the Italian and French versions, using
Zumbo criteria. RESULTS: Item response rates ranged from 87% to 97%. A floor
effect was found for three items. Results showed that the scale had a good reliabil-
ity (Cronbach’s alpha coefficients  0.75). Factor analyses demonstrated satisfac-
tory construct validity. Item internal consistency (IIC) and item discriminant valid-
ity criteria were met for most items (i.e. IIC was  0.40, and correlations between
items and their respective rest-scores in one dimension were all greater than cor-
relations with another dimension). The external validity was supported by corre-
lation of the different dimensions with the related clinical symptoms and related
generic QoL dimensions. The correlation between total H-QoL-I score and EQ-5D
index score was 0.78. No DIF was detected. CONCLUSIONS: These data support the
cross-cultural validity of the H-QoL-I to assess the health status of patients with HD
and integrate the patient perspective for Spain. A limitation of this study is the
small sample size.
PRM88
TRANSLATION AND VALIDATION OF OSTEOPOROSIS HEALTH BELIEF SCALE
INTO MALAYSIAN VERSION AMONG TYPE 2 DIABETICS PATIENTS
Abdulameer SA1, Syed Sulaiman SA1, Hassali MA1, Subramaniam K2, Sahib MN1
1Universiti Sains Malaysia, Minden, Penang, Malaysia, 2Penang General Hospital, George Town,
Penang, Malaysia
OBJECTIVES: To translate and examine the psychometric properties of the Malay-
sian version of the Osteoporosis Health Belief Scale (OHBS-M) among type 2 diabe-
tes patients (T2DM) and to determine the best cut-off value for OHBS-M with opti-
mum sensitivity and specificity. METHODS: A standard “forward–backward”
procedure was used to translate OHBS into Malay language. It was later validated
on a convenience sample of 250 T2DM outpatients between May and July 2011. The
psychometric assessment of this study was including validity (face validity, con-
tent validity ratio, and construct validity) and reliability (internal consistency and
test-retest). Sensitivity and specificity of OHBS-M were calculated using receiver
operating characteristic (ROC) curve analysis in comparison with the proxy gold
standard (quantitative ultrasound scan). RESULTS: The mean SD of OHBS-M
scores was 158.31 20.80. The Fleiss’ kappa, content validity ratio range and con-
tent validity index were 0.99, 0.75 to 1 and 0.886, respectively. Seven factors of the
OHBS-M were identified using exploratory factor analysis and were confirmed
through confirmatory factor analysis. Internal consistency and test–retest reliabil-
ity value were 0.89 and 0.61, respectively. The cut-off value of the OHBS-M was 169
with a sensitivity of 77.4% (95% CI 0.68- 0.84) and a specificity of 78.2% (95% CI 0.69-
0.85) to identify osteoporosis/osteopenia patients. The positive and negative pre-
dictive values were 78% (95% CI 0.68 - 0.85) and 77.6% (95% CI 0.68-0.84), respec-
tively. The area under the curve (AUC) for the OHBS-M was 0.877(95% CI 0.82-0.92).
According to QUS measurements, 20.4% were considered osteoporotic, while, 57.6
% osteopenic and 22 % normal. CONCLUSIONS: The findings of this study suggest
that the OHBS-M instrument is valid and reliable tool to be used in Malaysian
clinical setting.
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STANDARDIZING THE METRIC AND INCREASING THE EFFICIENCY OF
PHYSICAL FUNCTIONING OUTCOMES MEASUREMENT
Ware J1, Guyer R2, Harrington M2, Boulanger R2
1University of Massachusetts Medical School, Worcester, MA, USA, 2John Ware Research Group,
Worcester, MA, USA
OBJECTIVES: Item response theory (IRT) modeling evaluated the metric underlying
generic physical function (PF) surveys including SF-36, PROMIS and new PF cate-
gorical rating items and tested whether scores could be estimated more efficiently
while maintaining forward-backward comparability. METHODS: Generalized Par-
tial Credit Model (GPCM) estimates of parameters for MOS SF-36 PF-10, PROMIS
6-item PF and new (easy-hard) PF categorical rating items and model fit were tested
in a probability sample representing the general US population (N 625). Analyses
included: (a) fit of GPCM for 35-item bank; (b) item utilization in computerized
adaptive tests (CAT), (c) % at ceiling and floor; (d) % for whom reliability  0.90
(reliable range); (e) equivalence of mean norm–based scores (mean50, SD10) for
all measures across mild, moderate and severe chronically-ill groups, and (f) valid-
ity in predicting physical and emotional health general summary measures at a
9-month follow-up. RESULTS: The GPCM fit the data and item parameter estimates
agreed very well with those previously reported for MOS and PROMIS PF items. In
tests of discriminant validity, group means differed substantially across severity
groups (RV 0.81 to 1.00) and score equivalence across methods within each group
was confirmed (all differences 1 point). RV’s for standardized PF scores estimated
from new E-H items were equivalent to PF-10 and PROMIS PF estimations. Predic-
tive validity was equivalent and substantial (across methods) for physical and
significant, but lower, for emotional outcomes at 9 months, as hypothesized. The
most efficient (reduced respondent burden, comparable or improved reliability and
validity) measure was a new 6-item PF using E-H items and an improved adaptive
survey logic. CONCLUSIONS: Findings support the standardization of the metric
underlying PF measures and extend choice of methods to include more efficient
categorical rating scales that maintain forward-backward score comparability. Im-
proved adaptive survey logic reduces respondent burden and increases the reliable
range for estimates of scores for familiar legacy measures. This approach warrants
application to other generic health domains and tests of translated items and
standardized parameters across countries and languages.
PRM90
OUTCOME DIFFERENCES IN ALGORITHMS USED FOR INDIRECT MAPPING OF
UTILITY VALUES FROM HAQ-DI: AN ASSESSMENT BASED ON PHASE 2A
CLINICAL TRIAL DATA IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER
TREATMENT WITH NNC0109-0012 (ANTI-II-20 MAB)
Strandberg-Larsen M1, Hansen BB1, Göthberg M1, Valencia X2
1Novo Nordisk A/S, Søborg, Denmark, 2Novo Nordisk Inc, Princeton, NJ, USA
OBJECTIVES: A utility value is a preference-based measure for a person’s health-
related quality of life at a given point in time. In clinical trials the standard is to
measure utilities based on e.g. EQ-5D or HUI-3. However, in rheumatoid arthritis
(RA) there has been a tradition of estimating utility values indirectly from HAQ-DI.
This study used data from a phase 2a trial in RA patients after treatment with
NNC0109-0012 to assess outcome differences applying various indirect mapping
algorithms. METHODS: At least five different indirect mapping algorithms (UV1-5)
that translates HAQ-DI to EQ-5D or HUI3 utility values have been published. These
were applied to a phase 2a, multicentre, randomised, double-blind, multiple-dose,
placebo-controlled, parallel group trial investigating the clinical efficacy of
NNC0109-0012 in RA patients with active disease (Results reported elsewhere).
Physical function was a secondary objective measured by the change in HAQ-DI
from baseline to week 12. The analysis was performed with an ANOVA with treat-
ment as fixed factor. The following five algorithms were used: UV1(EQ-5D)0.9567–
0.309*HAQ-DI, Min;Max(0.03;0.96); UV2(HUI3)0.76–0.28*HAQ-DI0.05*(if Fe-
male), Min;Max(-0.08;0.81); UV3(HUI3)0.76–0.28*HAQ-DI0.05*(if
Female)0.001*Age, Min;Max(-0.06;0.91); UV4(HUI3)0.74–0.17*HAQ-DI, Min;
Max(0.23;0.74); and UV5(HUI3)0.9527–0.2018*HAQ-DI, Min;Max(0.35;0.95).
RESULTS: After 12 weeks the mean utility improvement within the active-group
across algorithms was 0.11 (range: 0.08-0.14) and 0.03 (range: 0.02-0.05) in the pla-
cebo-group. When comparing utility improvements between active and placebo
group across algorithms the difference was most pronounced when using UV3 
0.10 (range: 0.06-0.10) taking HAQ-DI, sex and age into account. CONCLUSIONS:
Choice of mapping algorithm for conversion of HAQ-DI into utilities impacts the
outcome in term of utility improvements, although the differences are small. Fu-
ture clinical trials using direct assessment of utilities will substantiate the potential
benefits of NNC0109-0012 for patients suffering from RA. Direct elicitations can
also be used to shed additional light on the validity of available indirect mapping
algorithms.
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HOW DO PATIENTS WITH DIFFERENT CONDITIONS DESCRIBE THEIR PAIN?
Martin ML1, Scanlon M2, McCarrier KP1, Wolfe M2, Bushnell DM2
1Health Research Associates, Inc., Seattle, WA, USA, 2Health Research Associates, Inc.,
Mountlake Terrace, WA, USA
OBJECTIVES: To identify descriptors that patients who have different physical con-
ditions use to describe the quality and severity of their pain, and to examine com-
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